For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Bortezomib; Docetaxel | Docetaxel will be given first at 40 mg/m2 IV on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1. Immediately afterwards, Bortezomib will be given at 1.6 mg/m2 IV on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1. | None | None | 11 | 25 | 0 | 25 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Vomitting | None | Gastrointestinal disorders | None | View |
| Hypercalcemia | None | Metabolism and nutrition disorders | None | View |
| Seizure | None | Nervous system disorders | None | View |
| Dry mouth | None | Gastrointestinal disorders | None | View |
| Death | None | General disorders | None | View |
| Diarrhea | None | Gastrointestinal disorders | None | View |
| Mucositis | None | Gastrointestinal disorders | None | View |
| Nausea | None | Gastrointestinal disorders | None | View |
| Hemorrhage, GI | None | Gastrointestinal disorders | None | View |